Tumour grade

What it is

Tumour grade is a pathology measure, usually on a 1-to-3 scale, of how abnormal cancer cells look and how aggressively they may behave. In simple terms, grade describes how closely cancer cells resemble normal tissue under the microscope. A low-grade (grade 1) tumour tends to look more like normal cells and often grows more slowly, while a high-grade (grade 3) tumour looks more abnormal and is more likely to grow and spread faster.

Grade is not the same as stage. Stage tells you how much cancer is present in the body, such as tumour size, lymph node involvement, or distant spread. Grade tells you about the tumour's microscopic behaviour and differentiation. Both matter, but they answer different questions.

Pathologists assign grade by examining tissue from a biopsy or surgery specimen. The exact grading system depends on the cancer type. Many cancers use a three-tier system, but some use four grades, low-versus-high grade categories, or disease-specific scoring systems. For example, breast cancer commonly uses the Nottingham histologic grade, while prostate cancer uses the Gleason Grade Group system rather than a simple 1-to-3 label.

A quick comparison:

Term	What it describes	Typical format
Grade	How abnormal the cancer cells look	Often 1, 2, or 3
Stage	How far the cancer has spread	Stage I-IV or TNM

How it works

Tumour grade reflects differentiation, meaning how much the cancer cells still resemble the normal cells they came from. Well-differentiated tumours usually keep more normal structure and function. Poorly differentiated or undifferentiated tumours have lost those features and often behave more aggressively.

When a pathologist grades a tumour, they may look at features such as:

1. Cell appearance: how abnormal the nuclei and cells look
2. Tissue architecture: whether the cells still form normal-looking glands, ducts, or other structures
3. Mitotic activity: how many cells are actively dividing
4. Necrosis or other aggressive features: in some tumour types

In breast cancer, the Nottingham system combines three microscopic features: tubule formation, nuclear pleomorphism, and mitotic count. The scores are added to classify the tumour as grade 1, 2, or 3. Reviews of breast cancer grading show that histologic grade has important prognostic value and remains part of routine pathology reporting.

Because grading is based on visual interpretation, there can be some variation between observers, especially for intermediate-grade tumours. This is one reason pathology reports may sometimes be reviewed again at a cancer centre before treatment decisions are finalised.

Evidence and uses

Tumour grade is used because it helps estimate prognosis and can influence treatment planning. In many cancers, a higher grade is associated with a greater chance of recurrence, faster growth, or worse survival, although the strength of that link varies by cancer type.

Breast cancer is a clear example. Histologic grade has long been shown to be an independent prognostic factor and is used along with tumour size and lymph node status in established prognostic tools. In practice, a high-grade breast cancer may support recommendations for more intensive systemic treatment than a low-grade cancer of similar size and stage.

Grade is commonly used in these ways:

Use of tumour grade	Why it matters
Prognosis	Helps estimate how aggressive the cancer may be
Treatment planning	May affect decisions about chemotherapy, radiation, or surveillance
Risk stratification	Used with stage, biomarkers, and patient factors
Pathology classification	Helps define tumour subtype in some cancers

That said, grade is only one part of the picture. Doctors usually interpret it together with:

• cancer type and subtype
• stage
• lymph node status
• molecular markers or biomarkers
• patient age, symptoms, and overall health

For example, in modern oncology, especially for breast cancer, grade is considered alongside hormone receptor status, HER2 status, genomic assays in selected cases, and imaging findings. In India, as elsewhere, multidisciplinary tumour boards often review these factors together when planning treatment.

Grade can also change in some situations. Research in recurrent breast cancer suggests that histologic grade may differ between the original tumour and a recurrence. This is one reason repeat biopsy may be recommended if cancer returns or behaves unexpectedly.

Diagnosis / how it's measured

Tumour grade is measured by a pathologist, not by a blood test or scan. The process usually involves these steps:

1. Tissue sampling by needle biopsy, endoscopy, or surgery
2. Microscopic examination of stained tissue sections
3. Application of a tumour-specific grading system
4. Reporting in the pathology report

A pathology report may say things like:

• low grade / intermediate grade / high grade
• grade 1 / grade 2 / grade 3
• well differentiated / moderately differentiated / poorly differentiated
• a disease-specific score such as Nottingham score or Gleason Grade Group

Important points about measurement:

• Biopsy grade may differ from final surgical grade because a small sample may not capture the whole tumour.
• Not all cancers are graded the same way. Some cancers are not routinely assigned a simple histologic grade.
• Intermediate categories can be less reproducible than clearly low- or high-grade tumours.
• Specialist review can matter, especially for rare cancers or when treatment decisions depend heavily on pathology details.

If you are reading your report, look for the exact wording used by the pathologist rather than assuming all grade systems mean the same thing across cancers.

When to see a clinician

Ask your treating clinician or pathologist to explain the grade if your report is unclear, especially if it may affect treatment choices. It is reasonable to ask how the grade fits with your stage, biopsy findings, imaging, and biomarkers.

You should also ask for clarification if:

• the report says the tumour is poorly differentiated, undifferentiated, or high grade
• the biopsy and surgery reports show different grades
• the report uses a disease-specific scoring system you do not understand
• a recurrence or metastasis has been biopsied and the new report differs from the original cancer

For patients in India, a second pathology review at a tertiary cancer centre may be useful when the diagnosis is rare, the report is ambiguous, or major treatment decisions depend on the grade.

Limitations and open questions

Tumour grade is useful, but it has limits. First, it is partly based on human interpretation, so there can be inter-observer variation, particularly for borderline or intermediate cases. Second, grade does not capture the full biology of cancer. Two tumours with the same grade can behave differently because of molecular changes, tumour microenvironment, or treatment response.

Another limitation is that grading systems are not uniform across all cancers. A grade 3 tumour in one cancer type is not directly comparable to grade 3 in another. Also, small biopsies may under-sample a heterogeneous tumour, so the final grade can change after surgery.

Current research is looking at whether digital pathology, artificial intelligence tools, and molecular profiling can improve consistency and prognostic accuracy. Evidence is promising in some settings, but these approaches are still being integrated into routine care and do not replace standard pathology at present.

The practical takeaway is that tumour grade is an important clue about cancer behaviour, but it works best when interpreted together with stage, biomarkers, imaging, and the overall clinical picture.